But, like Merck two weeks ago, GSK has failed to hit overall survival.
ApexOnco Front Page
Recent articles
Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.
NXP800 yields neither severe thrombocytopenia, nor any responses.
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
